MassimoCristofanilliMD

PubMed

• 32 citations
  Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative A...
  Richard S. Finn, Hope S. Rugo, Karen A. Gelmon, Massimo Cristofanilli, Marco Colleoni
  The Oncologist. 2021-05-01
• 22 citations
  Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology.
  Gabriele Di Sante, Jessica Pagé, Xuanmao Jiao, Omar Nawab, Massimo Cristofanilli
  Expert Review of Anticancer Therapy. 2019-06-20
• 1118 citations
  Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on prev...
  Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko, Jungsil Ro, Seock-Ah Im
  The Lancet. Oncology. 2016-04-01

Journal Articles

• Minimal Residual Disease in Patients with Nonmetastatic Triple-Negative Breast Cancer  
  Massimo Cristofanilli, MD, JAMA Oncology
• Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer  
  Massimo Cristofanilli, MD, The New England Journal of Medicine
• From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing  
  William J Gradishar, Al B Benson, Massimo Cristofanilli, Allison W Kurian, Value in Health
• Antitumor Response of an ERBB2 Amplified Inflammatory Breast Carcinoma With EGFR Mutation to the EGFR-TKI Erlotinib  
  Ali SM, Alpaugh RK, Buell JK, Stephens PJ, Yu JQ, Wu H, Hiemstra CN, Miller VA, Lipson D, Palmer GA, Ross JS, Cristofanilli M, Clin Breast Cancer, 2/1/2014
• Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor positive breast cancer  
  Jeselsohn R, Yelensky R, Buchwalter G, Frampton GM, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo A, Cristofanilli M, Gomez H, Arteaga CL, Giltn..., Clin Cancer Res, 1/7/2014
• The Third International Inflammatory Breast Cancer Conference  
  van Golen KL, Cristofanilli M, Breast Cancer Res, 11/5/2013
• Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory ...  
  Andreopoulou E, Vigoda IS, Valero V, Hershman DL, Raptis G, Vahdat LT, Han HS, Wright JJ, Pellegrino CM, Cristofanilli M, Alvarez RH, Fehn K, Fineberg S, Sparano JA, Breast Cancer Res Treat, 10/1/2013
• Presence of anaplastic lymphoma kinase in inflammatory breast cancer  
  Robertson FM, Petricoin Iii EF, Van Laere SJ, Bertucci F, Chu K, Fernandez SV, Mu Z, Alpaugh K, Pei J, Circo R, Wulfkuhle J, Ye Z, Boley KM, Liu H, Moraes R, Zhang X, ..., Springerplus, 10/1/2013
• A Comparison of Epidemiology, Biology, and Prognosis of Inflammatory Breast Cancer in Japanese and US Populations  
  Natori A, Hayashi N, Soejima K, Deshpande GA, Takahashi O, Cristofanilli M, Ueno NT, Yamauchi H, Clin Breast Cancer, 9/28/2013
• EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells  
  Mu Z, Li H, Fernandez SV, Alpaugh KR, Zhang R, Cristofanilli M, J Exp Clin Cancer Res, 9/1/2013
• Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?  
  Gazzaniga P, Raimondi C, Gradilone A, Biondi Zoccai G, Nicolazzo C, Gandini O, Longo F, Tomao S, Lo Russo G, Seminara P, Vincenzi B, Chimenti I, Cristofanilli M, Frati..., J Cancer Res Clin Oncol, 8/1/2013
• Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a...  
  Jiang ZF, Cristofanilli M, Shao ZM, Tong ZS, Song EW, Wang XJ, Liao N, Hu XC, Liu Y, Wang Y, Zeng L, Zhang M, Ann Oncol, 7/14/2013
• Circulating tumor DNA to monitor metastatic breast cancer  
  Cristofanilli M, Fortina P, N Engl J Med, 7/4/2013
• Inflammatory breast cancer (IBC): clues for targeted therapies  
  Fernandez SV, Robertson FM, Pei J, Aburto-Chumpitaz L, Mu Z, Chu K, Alpaugh RK, Huang Y, Cao Y, Ye Z, Cai KQ, Boley KM, Klein-Szanto AJ, Devarajan K, Addya S, Cristofa..., Breast Cancer Res Treat, 7/1/2013
• Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients  
  Giordano A, Gao H, Cohen EN, Anfossi S, Khoury J, Hess K, Krishnamurthy S, Tin S, Cristofanilli M, Hortobagyi GN, Woodward WA, Lucci A, Reuben JM, Ann Oncol, 6/24/2013
• Genome Wide Proteomics of ERBB2 and EGFR and Other Oncogenic Pathways in Inflammatory Breast Cancer  
  Zhang EY, Cristofanilli M, Robertson F, Reuben JM, Mu Z, Beavis RC, Im H, Snyder M, Hofree M, Ideker T, Omenn GS, Fanayan S, Jeong SK, Paik YK, Zhang AF, Wu SL, Hancoc..., J Proteome Res, 6/7/2013
• Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy  
  Tsai CJ, Li J, Gonzalez-Angulo AM, Allen PK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Yang W, Cristofanilli M, Valero V, Buchholz TA, Am J Clin Oncol, 5/2/2013
• Genomic and expression analysis of microdissected inflammatory breast cancer  
  Woodward WA, Krishnamurthy S, Yamauchi H, El-Zein R, Ogura D, Kitadai E, Niwa S, Cristofanilli M, Vermeulen P, Dirix L, Viens P, van Laere S, Bertucci F, Reuben JM, Ue..., Breast Cancer Res Treat, 4/1/2013
• An integrated analysis of three distinct IBC/nIBC Affymetrix gene expression data sets: uncovering the molecular secrets of IBC-biology  
  Van Laere S, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Iwamoto T, Van Dam P, Woodward WA, Cristofanilli M, Birnbaum D, Viens P, Dirix L, Reuben JM, Bertu..., Clin Cancer Res, 2/8/2013
• Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients  
  Giordano A, Egleston BL, Hajage D, Bland J, Hortobagyi GN, Reuben JM, Pierga JY, Cristofanilli M, Bidard FC, Clin Cancer Res, 1/22/2013
• A Chromosome-centric Human Proteome Project (C-HPP) to Characterize the Sets of Proteins Encoded in Chromosome 17  
  Liu S, Im H, Bairoch A, Cristofanilli M, Chen R, Deutsch EW, Dalton S, Fenyo D, Fanayan S, Gates C, Gaudet P, Hincapie M, Hanash S, Kim H, Jeong SK, Lundberg E, Mias G..., J Proteome Res, 1/4/2013
• The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis  
  Robertson FM, Chu K, Boley KM, Ye Z, Liu H, Wright MC, Moraes R, Zhang X, Green TL, Barsky SH, Heise C, Cristofanilli M, J Exp Ther Oncol, 1/1/2013
• A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer  
  Cristofanilli M, Johnston SR, Manikhas A, Gomez HL, Gladkov O, Shao Z, Safina S, Blackwell KL, Alvarez RH, Rubin SD, Ranganathan S, Redhu S, Trudeau ME, Breast Cancer Res Treat, 12/13/2012
• Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer  
  Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanill..., Mol Cancer Ther, 11/1/2012
• Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer  
  Rossi E, Fassan M, Aieta M, Zilio F, Celadin R, Borin M, Grassi A, Troiani L, Basso U, Barile C, Sava T, Lanza C, Miatello L, Jirillo A, Rugge M, Indraccolo S, Cristof..., Br J Cancer, 10/9/2012
• Join now to see all